Literature DB >> 23424373

Therapy optimization: a new model for managing high-cost biologics.

Thomas Morrow.   

Abstract

Disease management providers have largely ignored the less-common chronic diseases treated with expensive biologics, like multiple sclerosis. Here's how SPs can step in to provide much-needed therapy tracking services and cut the cost of care.

Entities:  

Year:  2006        PMID: 23424373      PMCID: PMC3571083     

Source DB:  PubMed          Journal:  Biotechnol Healthc        ISSN: 1554-169X


  6 in total

1.  Cost and health related quality of life consequences of multiple sclerosis.

Authors:  D T Grima; G W Torrance; G Francis; G Rice; A J Rosner; L Lafortune
Journal:  Mult Scler       Date:  2000-04       Impact factor: 6.312

2.  [Evaluation of drug treatment of disseminated sclerosis].

Authors:  P Thygesen
Journal:  Ugeskr Laeger       Date:  1965-11-11

Review 3.  The role of magnetic resonance techniques in understanding and managing multiple sclerosis.

Authors:  D H Miller; R I Grossman; S C Reingold; H F McFarland
Journal:  Brain       Date:  1998-01       Impact factor: 13.501

Review 4.  Treatment optimization in multiple sclerosis.

Authors:  Mark S Freedman; David G Patry; François Grand'Maison; Mary Lou Myles; Donald W Paty; Daniel H Selchen
Journal:  Can J Neurol Sci       Date:  2004-05       Impact factor: 2.104

5.  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910

6.  Neurourologic abnormalities in multiple sclerosis.

Authors:  I Goldstein; M B Siroky; D S Sax; R J Krane
Journal:  J Urol       Date:  1982-09       Impact factor: 7.450

  6 in total
  1 in total

1.  Impact of specialty drugs on the use of other medical services.

Authors:  Geoffrey F Joyce; Dana P Goldman; Pinar Karaca-Mandic; Grant D Lawless
Journal:  Am J Manag Care       Date:  2008-12       Impact factor: 2.229

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.